Excindogen / Vitalgenics - LARVOL DELTA

Vitalgenics Inc Has Unraveled the Mystery of Pancreatic Ductal Adenocarcinoma (PDAC). (Businesswire) - "In preclinical studies, immunotherapy drug Excindogen, has proven to inhibit the major sequences listed above, having the capability of 'turning off the faucet' and returning homeostasis back to normal so that T-cells can reactivate, attack and kill tumors, while programming adaptive immunity so the tumor has a less of a chance of returning. Preclinical studies have also shown that Excindogen is non- toxic with no major side effects which will make a huge impact with patients. Toxicity and side effects are the main reason patients are non-compliant with current chemotherapy drugs....Vitalgenics Inc, is seeking capital to enter a phase 1/2 clinical trial and FDA submissions for advanced stage pancreatic cancer."

Financing • Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer